Cancer Immunotherapy
Electroporated dendritic cells are powerful cytotoxic T lymphocyte stimulators
Published in Gene Therapy Weekly, October 23rd, 2003
According to published research from Belgium, "genetically modified dendritic cells (DC) constitute a promising approach in cancer immunotherapy. Viral gene delivery systems have been shown to be very efficient strategies, but safety concerns for their clinical use in immunotherapy remain an important issue. Recently, the technique of mRNA electroporation was described as a very efficient tool for the genetic modification of human monocyte-derived DC."
"Here, we show that transgene expression can be modulated by varying the amount of mRNA used for electroporation. We...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-10-23)
More Articles from Gene Therapy Weekly
- Melanoma
Apoptotic tumor cells prime immune responder cells against cancer - Stem-Cell Research
Stem cells modified with Akt restore function after cardiac infarction - Oncology
CD40 ligand gene therapy has the potential to treat malignant mesothelioma - Oncology
New cancer gene therapy restricts treatment to liver cancer cells - Oncology
Suppression of the E6AP gene could potentially treat HPV-positive cells - Atherosclerosis
Leptin resistance may cause arterial disease in those with metabolic syndrome - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
